Resources and Evidence Contact us

Company overview

Prolacta Bioscience is a privately held, global life sciences company dedicated to Advancing the Science of Human Milk to improve the health of premature and critically ill infants. Prolacta's 100% human milk–based nutritional products have been evaluated in more than 20 clinical studies published in peer-reviewed journals. More than 80,000 premature infants have benefitted from Prolacta’s nutritional products worldwide to-date.*

Established in 1999, Prolacta is the world’s leading provider of human milk–based nutritional products for hospital use and is also exploring the therapeutic potential of human milk across a wide spectrum of diseases. Prolacta maintains the industry’s strictest quality and safety standards for screening, testing and processing human donor milk.

Operating the world’s first pharmaceutical-grade human milk processing facilities, Prolacta uses vat pasteurisation and a patented, U.S. Food and Drug Administration (FDA)-reviewed manufacturing process to ensure pathogen inactivation, while protecting the nutritional composition and bioactivity of its human milk–based products.1,2 Prolacta is a global company with headquarters in Duarte, California.

Media contact
Loren Kosmont

*Estimated number of premature infants fed Prolacta’s products from January 2007 to December 2021; data on file.

Press + news

See all
  • Press releases
  • Prolacta in the news

Multiple peer-reviewed studies show Prolacta’s 100% human milk-based nutritional fortifiers reduce risk of life-threatening comorbidities in premature infants, compared to cow milk-based nutrition

Prolacta Bioscience introduces its first evidence-based feeding protocol for an exclusive human milk diet in the NICU

Prolacta Bioscience appoints David Steinberg as chief financial officer

International Conference on Human Milk Science & Innovation to discuss latest research on bioactivity and neurodevelopment

Alecia-Jane Twigger, Ph.D., wins the Ruth A. Lawrence Investigator Award for outstanding contributions to advancing human milk science

Independent, head-to-head study shows significant health benefits of early fortification associated with Prolacta Bioscience’s 100% human milk-based fortifiers compared to cow milk-based fortifiers for premature infants

Should human milk-based nutritional products for premature infants be homogenized? More research is needed, new journal article says

Prolacta Bioscience enrolls first infant in Japan-based clinical trial to evaluate the effect of an Exclusive Human Milk Diet on growth and safety in premature infants

Prolacta Bioscience Appoints Dr. Anne Beal to Board of Directors

Prolacta Bioscience Celebrates Prematurity Awareness Month by Recognizing Breast Milk Donors for Their Contributions to Premature Infants in the NICU

Prolacta Bioscience Develops World’s First Test to Directly Detect Bacteria and Viruses, Including SARS-CoV-2, in Donor Breast Milk

Mindy Fuzesy presents at Association of Women's Health, Obstetric and Neonatal Nurses 2021 virtual convention

Prolacta Bioscience continues Advancing the Science of Human Milk, proud to partner with NICU teams in saving lives of premature infants

Association of Women’s Health, Obstetric, & Neonatal Nurses (AWHONN) encourages an exclusive human milk diet (EHMD) for vulnerable preterm infants in the neonatal intensive care unit (NICU)

Prolacta Bioscience hosts panel session on the need for uniform human milk safety standards at 2021 National Coalition for Infant Health Summit

Prolacta Bioscience supports Breastfeeding Awareness Month with donation of breast pumps to Alliance for Black NICU Families

Prolacta Bioscience congratulates Carolyn TenEyck, RN, on lifetime achievement award from National Black Nurses Association

Enrollment completed in clinical trial evaluating effect of exclusive human milk diet including a specialty fortifier in term infants born with single ventricle physiology

Four studies showed Prolacta Bioscience’s 100% human milk-based fortifiers reduced retinopathy of prematurity (ROP) in premature infants

Prolacta Bioscience provides update on latest SARS-CoV-2 data and continued safety of its human milk-based nutritional products

Late-onset sepsis reduced in premature infants fed Prolacta’s 100% human milk-based fortifiers as part of an exclusive human milk diet

Research suggests some premature infants may go home from the NICU Up to 3 weeks earlier when fed Prolacta’s 100% human milk-based nutritional products; those with bronchopulmonary dysplasia may benefit the most

Prolacta Bioscience fortifiers reduce risk of serious lung disease and hospital costs among premature infants, compared to cow milk-based fortifiers

Multiple NICUs showed improved growth & lung health in premature infants by fortifying feeds safely in the first days of life with Prolacta’s 100% human milk-based fortifiers

The preemie parent’s survival guide to the NICU now reflects the latest clinical advancements to better support parents worldwide

Upcoming events

All events